CN106999524A - The composition for being used to prevent and treat hypertrophy of the prostate containing ginseng seed oil - Google Patents
The composition for being used to prevent and treat hypertrophy of the prostate containing ginseng seed oil Download PDFInfo
- Publication number
- CN106999524A CN106999524A CN201580059489.2A CN201580059489A CN106999524A CN 106999524 A CN106999524 A CN 106999524A CN 201580059489 A CN201580059489 A CN 201580059489A CN 106999524 A CN106999524 A CN 106999524A
- Authority
- CN
- China
- Prior art keywords
- ginseng seed
- seed oil
- composition
- prostate
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 76
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 74
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 43
- 210000002307 prostate Anatomy 0.000 title claims abstract description 20
- 241000208340 Araliaceae Species 0.000 title claims abstract 6
- 206010020880 Hypertrophy Diseases 0.000 title claims description 14
- 235000013305 food Nutrition 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 5
- 240000004371 Panax ginseng Species 0.000 description 70
- 238000009472 formulation Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 12
- 230000027939 micturition Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229930016911 cinnamic acid Natural products 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940070765 laurate Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QYIMSPSDBYKPPY-RSKUXYSASA-N (S)-2,3-epoxysqualene Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C=C(/C)CC\C=C(/C)CC[C@@H]1OC1(C)C QYIMSPSDBYKPPY-RSKUXYSASA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UHOPWFKONJYLCF-UHFFFAOYSA-N 2-(2-sulfanylethyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCS)C(=O)C2=C1 UHOPWFKONJYLCF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 150000005204 hydroxybenzenes Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to the composition effective to the loose prevention and treatment of male prostate containing ginseng seed oil.
Description
Technical field
The present invention relates to the composition effective to the loose prevention and treatment of male prostate containing ginseng seed oil.
Background technology
Ginseng (Panax ginseng C.A.Meyer) is to belong to the plant of Araliaceae Panax, be South Korea, China,
The place such as Japan began to the crude drug used before 2000, rule of thumb made by prevention disease and for the purpose of the extension life-span
With effect and effect of hitherto known ginseng include：The effect of Central nervous system, anticarcinogenesis, anticancer are lived
Property effect, Immunologic Functions, antidiabetic effect, hyperfunction of liver effect, improve cardiovascular disorder, anti arteriosclerosis
Effect, Blood pressure regulation, improvement climacteric obstacle, the effect brought to osteoporosis, resistance to compression effect, antifatigue work
With, antioxidation activity, suppress (the newest Korean ginseng " composition and effect ", ginseng tobacco research institute of South Korea, 56- such as aging effect
112,1996).
On the other hand, ginseng seed contains about 15~26% oil (Beveridge etc. 2002；Matsum oto etc. 1986),
It is used as main fatty acid component, monounsaturated fatty acids oleic acid (C18:1) content is high, therefore is shown as with similar to olive oil
Aliphatic acid composition.
And, it has been found that there is the various plants sterol of reduction blood cholesterol in ginseng seed oil, such as
Squalene, oxidosqualene, campesterol, stigmasterol, sitosterol etc., thus as functional raw material using ginseng seed oil can
Energy property is in rising trend.In addition, it was reported that the research on ginseng seed carried out so far is included on ginseng seed and people
Research (Hu etc. 2008), the studying of composition on ginseng seed and the saponin(e of pulp, the different productions of the panaxoside composition of ginseng root
The anti-oxidant effect of the composition of the ginseng seed oil on ground and the brought ginseng seed of comparative studies, the autoclaving processing of oxidation stability
Fruit etc., the research of the composition of composition and ginseng seed oil primarily with regard to the panaxoside of ginseng seed.Although carrying out this lasting
The bromatology value correlative study of ginseng seed oil is planted, but compared with the research of ginseng and fruit, its achievement is insignificant.
The content of the invention
The technical problem to be solved
In this regard, result of the present inventor's research ginseng seed oil to the new application of health, it was found that ginseng seed oil is to man
Property hypertrophy of the prostate has effective mitigation, so as to complete the present invention.Therefore, it is an object of the present invention to provide having
The loose composition of effect prevention and treatment male prostate, the composition contains ginseng seed oil.
Technical scheme
To achieve these goals, the present invention is provided containing ginseng seed oil as active ingredient for preventing and treating man
The composition of property hypertrophy of the prostate.
Invention effect
The composition of the present invention effectively can alleviate and prevent male prostate loose, in addition, help to promote people
Body health, such as to setting up, reducing body weight, improvement cholesterol and neutral fat, therefore, it is possible to be widely used in food and
Field of medicaments.
Brief description of the drawings
Fig. 1 is the chart for the step for showing processed ginseng seed oil.
Preferred forms
The present invention relates to containing ginseng seed oil, the prevention and treatment to the loose symptom of male prostate have useful effect
Composition.
The processing method of ginseng seed oil used in the present invention is simultaneously not particularly limited, for example can be according to Fig. 1
Procedure of processing prepare.Specifically, including following process.
(a) the step of obtaining ginseng seed from ginseng fruit；And
(b) step of ginseng seed oil is extracted oil and obtained to the ginseng seed obtained in above-mentioned steps.
Ginseng seed in the step (a) includes germination or the ginseng seed not germinateed, can be stranger's ginseng seed, can also
It is the ginseng seed being dried by solar drying or heated-air drying.
The method that ginseng seed is extracted oil is not particularly limited in the present invention, it is possible to use known various methods.
In one embodiment of the present invention, ginseng seed oil of the invention can be by the way that ginseng seed to be put into oil press
Row squeezes and extracts the pressing method of the squeezing ginseng seed of useful component to obtain.Now, if food oil press, then may be used
To use without restriction, the oil expression time is preferably 3~20 minutes, and oil expression is generally carried out at normal temperatures.
In another embodiment of the present invention, ginseng seed oil can pass through super critical extraction (Supercritical
Water Extraction) extract.Means of supercritical extraction be using surmounting the supercritical fluid of critical dotted state, it is used super to face
The species of boundary's fluid is simultaneously not particularly limited, and can use pentane, carbon dioxide etc., can preferably use carbon dioxide.Separately
Outside, the species of used solvent and it is not particularly limited, alcohol or pure water conduct can be preferably used in the present invention
Solvent.
In another embodiment of the present invention, ginseng seed oil can pass through sub-sigmaritical extraction method (Sub critical
Water Extraction) extract.Sub-critical extraction be use not less than critical point in the state of solvent as Extraction solvent,
It can be shown and not limited particularly with means of supercritical extraction identical effect, used solvent species according to the selection of solvent
It is fixed, alcohol or pure water can be preferably used in the present invention as solvent.
In another embodiment of the present invention, ginseng seed oil can be extracted by microwave loss mechanisms.Microwave loss mechanisms are
The method of composition, is used needed for can in a short time being extracted while reducing solvent and saving energy to greatest extent
Solvent species and be not particularly limited, alcohol or pure water can be preferably used in the present invention as solvent.
In another embodiment of the present invention, ginseng seed oil can be extracted by ultrasonic extraction.Ultrasonic wave extraction
Method for can in the case of the modification or loss without extract the efficiently method of effective component extracting, institute in a short time
The solvent species that uses simultaneously is not particularly limited, and alcohol or pure water can be preferably used in the present invention as solvent.
In the composition of the present invention, according to the form of composition, relative to composition total weight, can containing 0.01~
The ginseng seed oil of 100 weight % amount.
In addition, the composition of the present invention can turn to tablet, pill, sublimed preparation with formulationCapsule, granule,
The pharmaceutical compositions or food compositions of the forms such as powder, ointment, drink or injection.
The present invention provides the pharmaceutical compositions containing ginseng seed oil extract according to conventional methods.In the preparation of pharmaceutical formulation
In, preferably active component is mixed together or diluted with carrier, or is encapsulated in the carrier of container form.Carrier is used as dilution
Agent is in use, can be that carrier is act as to active component, the curable type of excipient or medium (medium), half curable type or liquid
Material.Therefore, formulation can be tablet, it is pill, pulvis, sachet (sachet), elixir (elixir), suspending agent, emulsion, molten
The forms such as liquor, syrup, aerosol, soft or hard gelatine capsule, sterile injectable preparation, sterilizing powder.
Suitable carrier, excipient and diluent can be exemplified as lactose, glucose, sucrose, D-sorbite, mannitol,
Calcium silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, hydroxy benzenes first
Propyl propionate, talcum powder, magnesium stearate and mineral oil.Filler, anti-coagulants, lubricant, moistening can be further included in formulation
Agent, spices, emulsifying agent, preservative etc..The composition of the present invention can use method well known in the art to carry out formulation so that apply
Quick, lasting or sustained release for active component can be provided after mammal.
The present invention pharmaceutical compositions can be applied by number of ways, it include orally, percutaneously, subcutaneously, vein, abdomen
Chamber, muscle, partial smearing, paster and ion infiltration (iontophoresis) etc., wherein, it is preferably that part is applicable and orally applied
With.
For people, the conventional amount of application on the 1st of reactive compound is 1~100mg/kg body weight, preferably can for 5~
The scope of 70mg/kg body weight, can for several times be applied with one-time use or be divided into.However, the actual amount of application of active component should be managed
Xie Weiying is in view of disease, route of administration, the age of patient, sex and body weight, the order of severity of disease etc. to be treated is a variety of
Correlative factor is determined.Therefore, the amount of application can't limit the scope of the present invention in any way.
In addition, the present invention provides the food compositions containing ginseng fruit extract according to the conventional method.
The food compositions of the present invention have liquid or the formulation of solid state, and formulation is simultaneously not particularly limited, for example
Tablet, granule, drink, caramel, fat-reducing rod (dietbar) etc. can be turned to formulation.Removed in the food compositions of various formulations
Beyond active ingredient, those skilled in the art easily can suitably select conventional in the field according to formulation or application target
The composition that uses simultaneously is mixed, and when with other raw materials simultaneously in use, producing synergy.
Embodiment
Hereinafter, the present invention is illustrated by following embodiment and test example.Embodiment and test example are intended in more detail
Illustrate the present invention, the scope of the present invention is not limited to the scope of following embodiments.
In addition, this area has a case that the people of usual knowledge can be in the technological thought category without departing from the present invention
Under, it is obvious that various modifications are carried out within the scope of the appended claims and are imitated.
The preparation of [embodiment 1] ginseng seed oil
The pretreatment of ginseng seed
The fruit of stranger's ginseng is harvested, seed is separated, so as to harvest ginseng seed.
The preparation of ginseng seed oil
At normal temperatures using food oil press (DS-1500, DASAN food industries machinery, South Korea) 5 minutes, so that from
Ginseng seed oil has been obtained in the ginseng seed being obtained as described above (yield is 0.5~2%).
The ginseng seed so obtained oil is used for following test examples.
[test example 1]
<The aliphatic acid of ginseng seed oil and the analysis result of lipid>
The aliphatic acid and lipid analysis result of the ginseng seed oil prepared in embodiment 1 are as follows.
Table 1
| Composition | Content |
| Laurate (mg/100g) | 2.5 |
| Phytosterol (mg/100g) | 7.38 |
| Phytosterin ester (mg/100g) | 10.5 |
| CLA (mg/100g) | 1.4 |
| Trans- 9, trans- 11 CLA (mg/100g) | 1.04 |
| N-octacosanol (mg/100g) | 0.005 |
| Phosphatide (mg/100g) | 20.21 |
| Gamma-Linolenic acid (mg/100g) | 1.36 |
As shown in the result of above-mentioned table 1, aliphatic acid and lipid are detected in the ginseng seed oil of the present invention.
The related Evaluation on quality of life questionnaire (BPH QoL-k1) of [test example 2] hypertrophy of the prostate
In order to evaluate the quality of life that hypertrophy of the prostate is related, South Korea following items are implemented survey (on
The questionnaire exploitation of the related quality of life of hypertrophy of the prostate：Reliability and feasibility checking, great Han urology proceedings, volume 41 1
Number, 35-46 in 2000).
(1) it is usually inconvenient because of frequent micturition.
(2) it is inconvenient because often to get up urination during sleep at night.
(3) after urination, underwear is got wet and inconvenient because urine can still be dripped.
(4) impatient can not but urinate in time and it is inconvenient.
(5) still there is the sensation of non-emptying after urinating and inconvenient.
(6) it is inconvenient because suppressing urine difficulty.
(7) it is inconvenient because of weak stream of urine.
(8) dysuria when because of physical fatigue and it is inconvenient.
(9) it is inconvenient because of the heavy and stiff sensation of genital area.
(10) after urination, still feel that belly is heavy and shouting pain and it is inconvenient.
(11) worry frequent micturition without having a drink.
(12) work is influenceed because of frequent micturition.
(13) it is inconvenient because of frequent micturition during long-distance travel.
(14) because going the frequency of toilet more and inconvenient than others in feast.
(15) go to climb the mountain or carry out outdoor sports inconvenience.
(16) because of frequent micturition, feel to take great energy to outgoing.
(17) feel long-time uneasy and nervous by bus.
(18) it is difficult to enter deep sleep.
(19) it is not positive to every thing, without desire.
(20) it is difficult that something is focused on.
(21) no special the reason for, also can often fly into a rage.
(22) unnecessarily everything is all worried about or worried more.
(23) because of frequent micturition, it is difficult to participate in and such as go to church, the religious activities such as monastery.
(24) to attending a party and other people are gregarious feels to take great energy.
(25) healthy living can be crossed to old age without confidence.
(26) health status of oneself is worried very much.
(27) whether worry can with age, and the state of an illness can further deteriorate, and need to receive continued treatment.
(28) it is pernicious to worry the metabasis of oneself.
(29) if symptom further deteriorates and be able to not can urinated worry in the future.
(30) sexual desire is reduced than in the past.
(31) it is difficult to erect.
(32) atrophy at once or it can not can also be ejaculated to one's great satisfaction even if having erected.
(33) seem what has not enough and without confidence in terms of property.
(34) fatigue is often felt like.
(35) it is difficult to voluntary activity because of physically-draining.
With corresponding to " 0：Completely without inconvenience；1：Almost without inconvenience；2：It can stand；3：Inconvenience；4：It is very inconvenient；5
It can not stand." fraction above-mentioned 35 projects are detected, and total total score, the quality of life related to hypertrophy of the prostate
Evaluated.
60 are usually felt urination the male of more than 40 years old of inconvenience carries out first time questionnaire as object and made
Diagnosis questionnaire, is then divided into 3 groups by above-mentioned 60 with every group 20.For wherein 1 group, by the ginseng seed of above-described embodiment 1
Oil is fitted into and can be divided into 1ml straw container, and taking 28 times makes it be contained in milk and be absorbed.That is, often daily ingestion 1 time
The ginseng seed oil (ginseng seed oil intake group) of 28ml standardization.In addition, to another group, in order to be compared, making it absorb the moon
Cinnamic acid.Specifically, 2.5mg laurate is dissolved in 1ml soya-bean oil, makes the group often 1 28ml of the daily ingestion dissolving moon
Soya-bean oil (that is, total lauric acid content is 70mg, identical with lauric amount contained in 28ml ginseng seed the oil) (moon of cinnamic acid
Cinnamic acid intake group).In addition, to other another group, 1 28ml of the intake soya-bean oil for not containing other active ingredients (is not absorbed daily
Group).After absorbing about 4 weeks as described above, diagnosis questionnaire is made again, so that before and after to intake ginseng seed oil, laurate or soya-bean oil
Compare.
Result is to be shown in diagnosing the change of questionnaire assessment fraction in table 2 below (N=60).
Table 2
As shown in upper table 2, it is known that the diagnosis questionnaire assessment fraction of the subjects of intake ginseng seed oil is lower, with intake
Know for by making prostate smooth musculature cells relaxation alleviate prostate hypertrophy symptomatology and the lauric feelings favourable to prostate health
Condition is compared, and it is significantly higher that it improves degree.Therefore, thus, it is possible to confirm that intake ginseng seed oil improves prostate hypertrophy symptomatology.
The formulation example to the composition of one embodiment of the invention is illustrated below, but it is also possible to which application is other a variety of doses
Type, it is only used for illustrating, rather than in order to limit the present invention.
[formulation example 1] ginseng seed 100% concentrate of oil (extract)
When the ginseng seed for preparing embodiment 1 is oily, carrying out concentration makes its solids content reach more than 20%, ripe at low temperature
After change, 100% concentrate product of liquid form is prepared into.
[formulation example 2] soft capsules
By the ginseng seed oil of 100mg embodiment 1,0.8mg palm oil, 0.48mg hydrogenated vegetable oil, 2.4mg
Cera flava and 3.6mg lecithin are mixed, and are filled according to the conventional method and are prepared for soft capsule.
[formulation example 3] tablet
The dextrin of the ginseng seed oil, 200mg glucose and 196mg of 160mg embodiment 1 is mixed, and utilized
Fluidized bed dryer is granulated, and then adds 7mg sugar ester (sugar ester), and is carried out tabletting with tablet press machine and be prepared for piece
Agent.
The preparation of [formulation example 4] ball
The ginseng seed oil of 0.9g embodiment 1,0.3g sugar, 1.91g starch and 0.56g glycerine are mixed,
And ball is prepared for using pellet processing machine.
[formulation example 5] granule
The dextrin of the ginseng seed oil, 200mg glucose and 196mg of 160mg embodiment 1 is mixed, stream is utilized
Change after bed dryer granulation, be filled into bag and be prepared for granule.
[formulation example 6] drink
The citric acid of the ginseng seed oil, 10g glucose and 2g of 110mg embodiment 1 is mixed, then added
188g pure water is simultaneously filled into bottle, and it is 200ml to make every bottle.After being filled into bottle, sterilizing 2~3 hours is carried out at 90 DEG C
And it is prepared for beverage.
Claims (4)
1. the composition for preventing and treating hypertrophy of the prostate, it is characterised in that the composition contains the oily conduct of ginseng seed
Active ingredient.
2. the composition according to claim 1 for being used to prevent and treat hypertrophy of the prostate, it is characterised in that relative to group
Compound gross weight, the ginseng seed oil containing 0.01~100 weight %.
3. the composition according to claim 1 or 2 for being used to prevent and treat hypertrophy of the prostate, it is characterised in that described
Combination dosage form turns to pharmaceutical compositions or food compositions.
4. in the composition containing ginseng seed oil, application of the ginseng seed oil in terms of for preventing and treating hypertrophy of the prostate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140149716A KR102273967B1 (en) | 2014-10-31 | 2014-10-31 | Composition for preventing and treating prostatic hypertrophy containing ginseng seed oil |
| KR10-2014-0149716 | 2014-10-31 | ||
| PCT/KR2015/011246 WO2016068547A1 (en) | 2014-10-31 | 2015-10-23 | Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106999524A true CN106999524A (en) | 2017-08-01 |
| CN106999524B CN106999524B (en) | 2021-01-15 |
Family
ID=55857807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580059489.2A Active CN106999524B (en) | 2014-10-31 | 2015-10-23 | Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6615200B2 (en) |
| KR (1) | KR102273967B1 (en) |
| CN (1) | CN106999524B (en) |
| WO (1) | WO2016068547A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210121892A (en) * | 2020-03-31 | 2021-10-08 | (주)아모레퍼시픽 | Composition comprising ginseng seed oil |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065836A (en) * | 2008-06-13 | 2011-05-18 | 株式会社爱茉莉太平洋 | External preparation composition for skin comprising ginseng flower or ginseng seed extracts |
| KR20140055348A (en) * | 2012-10-31 | 2014-05-09 | 세명대학교 산학협력단 | Extract of ginseng seed, composition or oil having the same, and preparing method thereof |
| KR101452320B1 (en) * | 2014-03-11 | 2014-10-22 | 주식회사 벤스랩 | FERMENTED CAMELLIA JAPONICA SEED OIL INHIBITING 5-α REDUCTASE FOR IMPROVEMENT OF BENIGN PROSTATIC HYPERPLASIA AND ALOPECIA |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23256A1 (en) * | 2003-03-20 | 2008-01-24 | Dalmer Lab Sa | EXTRACT OBTAINED FROM ROYSTONEA REGIA FRUITS USED AGAINST PROSTATE HYPERPLASIA AND PROSTATITIS |
| CN101134054A (en) * | 2006-08-30 | 2008-03-05 | 北京欧纳尔生物工程技术有限公司 | Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same |
| KR101280300B1 (en) * | 2011-05-04 | 2013-07-01 | 이현기 | Health-aid food used the ginseng seed oil by main raw material |
| KR101790131B1 (en) * | 2011-09-16 | 2017-10-25 | 초임계연구소 주식회사 | Process for Preparing Ginseng seed Oil of High Oxidative Stability and Low Color with Supercritical Fluid |
-
2014
- 2014-10-31 KR KR1020140149716A patent/KR102273967B1/en active IP Right Grant
-
2015
- 2015-10-23 CN CN201580059489.2A patent/CN106999524B/en active Active
- 2015-10-23 WO PCT/KR2015/011246 patent/WO2016068547A1/en active Application Filing
- 2015-10-23 JP JP2017523344A patent/JP6615200B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065836A (en) * | 2008-06-13 | 2011-05-18 | 株式会社爱茉莉太平洋 | External preparation composition for skin comprising ginseng flower or ginseng seed extracts |
| KR20140055348A (en) * | 2012-10-31 | 2014-05-09 | 세명대학교 산학협력단 | Extract of ginseng seed, composition or oil having the same, and preparing method thereof |
| KR101452320B1 (en) * | 2014-03-11 | 2014-10-22 | 주식회사 벤스랩 | FERMENTED CAMELLIA JAPONICA SEED OIL INHIBITING 5-α REDUCTASE FOR IMPROVEMENT OF BENIGN PROSTATIC HYPERPLASIA AND ALOPECIA |
Non-Patent Citations (3)
| Title |
|---|
| 杨必成等: "治疗良性前列腺增生的天然药物研究进展", 《中草药》 * |
| 谢宏等: "冷榨人参籽油与热榨人参籽油的品质比较", 《中国油脂》 * |
| 钱余等: "《专家解答前列腺增生》", 30 June 2014, 第二军医大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016068547A1 (en) | 2016-05-06 |
| JP6615200B2 (en) | 2019-12-04 |
| KR102273967B1 (en) | 2021-07-08 |
| KR20160052001A (en) | 2016-05-12 |
| JP2018500285A (en) | 2018-01-11 |
| CN106999524B (en) | 2021-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Javan et al. | Breastfeeding: A review of its physiology and galactogogue plants in view of traditional Persian medicine | |
| CN1322821C (en) | Natto powder and preparing method and health food containing such natto powder | |
| US4886665A (en) | Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care | |
| US20060002954A1 (en) | Composition trapping radicals in organism | |
| KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
| CN106942748A (en) | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof | |
| WO2012097578A1 (en) | Pharmaceutical composition for spleen and stomach caring and preparation method therefor | |
| KR101579845B1 (en) | Composition that comprising fenugreek extract or compound including fenugreek extract for preventing and improving the andropause or male menopause symptom which involves lethargy, hypotrophy, muscle weakness, increasing visceral fat, tiredness and stress, by increasing testosterone level, endurance, muscle mass and decreasing visceral fat and improving blood lipid composition, number of sperm and activation of sperm | |
| KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
| CN104383156B (en) | A kind of composition with weight-reducing and blood fat reducing function and preparation method thereof and purposes | |
| US20190192601A1 (en) | Extracts of cyclanthera pedata and formulations and uses thereof | |
| JP2018521003A (en) | Composition for prevention or treatment of benign prostatic hyperplasia containing sykunshi extract | |
| CN113164541B (en) | Composition for preventing, treating or improving male climacteric syndrome comprising Sambucus nigra extract as active ingredient | |
| CN106999524A (en) | The composition for being used to prevent and treat hypertrophy of the prostate containing ginseng seed oil | |
| CN102238956A (en) | Combination therapy comprising actinidia and steroids and uses thereof | |
| KR20200025245A (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
| KR101934810B1 (en) | Preparation for improving blood circulation comprising oriental medicinal extracts | |
| CN107347997A (en) | Milk containing high-calcium aizoon stonecrop herb and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| KR20110000250A (en) | Health-supplementary food utilizing natural material for the healthy prostate and method of manufacturing thereof | |
| CN111821325A (en) | Application of photorhaponticum flower extract | |
| JP2006069970A (en) | Composition for preventing male climacteric disorder and beverage and foods including the same | |
| Jin et al. | The hypoglycemic effect of aqueous seed extract of Parkia speciosa on rats | |
| TW201834680A (en) | Composition for prevention improvement or treatment of precocious puberty comprising extracts of Coix lacryma-jobi L var ma-yuen Stapf seed and Artemisia capillaris Thunberg as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |